Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1999 May;36(5):398–404.

Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria

P Arvio 1, M Arvio 1, M Kero 1, S Pirinen 1, P Lukinmaa 1
PMCID: PMC1734365  PMID: 10353787

Abstract

Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by deficiency of aspartylglucosaminidase (AGA). The main symptom is progressive mental retardation. A spectrum of different mutations has been reported in this disease, one missense mutation (Cys163Ser) being responsible for the majority of Finnish cases. We were able to examine 66 Finnish AGU patients for changes in the oral mucosa and 44 of these for changes in facial skin. Biopsy specimens of 16 oral lesions, 12 of them associated with the teeth, plus two facial lesions were studied histologically. Immunohistochemical staining for AGA was performed on 15 oral specimens.
  Skin was seborrhoeic in adolescent and adult patients, with erythema of the facial skin already common in childhood. Of 44 patients, nine (20%) had facial angiofibromas, tumours primarily occurring in association with tuberous sclerosis. Oedemic buccal mucosa (leucoedema) and gingival overgrowths were more frequent in AGU patients than in controls (p<0.001).
  Of 16 oral mucosal lesions studied histologically, 15 represented fibroepithelial or epithelial hyperplasias and were reactive in nature. Cytoplasmic vacuolisation was evident in four. Immunohistochemically, expression of AGA in AGU patients' mucosal lesions did not differ from that seen in corresponding lesions of normal subjects. Thus, the high frequency of mucosal overgrowth in AGU patients does not appear to be directly associated with lysosomal storage or with alterations in the level of AGA expression.


Keywords: aspartylglucosaminidase; lysosomal storage disease; oral mucosa; skin tumours

Full Text

The Full Text of this article is available as a PDF (239.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvio M. A., Rapola J. M., Pelkonen P. M. Chronic arthritis in patients with aspartylglucosaminuria. J Rheumatol. 1998 Jun;25(6):1131–1134. [PubMed] [Google Scholar]
  2. Arvio M., Autio S., Louhiala P. Early clinical symptoms and incidence of aspartylglucosaminuria in Finland. Acta Paediatr. 1993 Jun-Jul;82(6-7):587–589. doi: 10.1111/j.1651-2227.1993.tb12761.x. [DOI] [PubMed] [Google Scholar]
  3. Arvio M. Follow-up in patients with aspartylglucosaminuria. Part I. The course of intellectual functions. Acta Paediatr. 1993 May;82(5):469–471. doi: 10.1111/j.1651-2227.1993.tb12725.x. [DOI] [PubMed] [Google Scholar]
  4. Arvio M. Follow-up in patients with aspartylglucosaminuria. Part II. Adaptive skills. Acta Paediatr. 1993 Jun-Jul;82(6-7):590–594. doi: 10.1111/j.1651-2227.1993.tb12762.x. [DOI] [PubMed] [Google Scholar]
  5. Arvio P., Arvio M., Pirinen S. Characteristic dental arches and occlusion in patients with aspartylglucosaminuria. J Craniofac Genet Dev Biol. 1997 Jul-Sep;17(3):133–140. [PubMed] [Google Scholar]
  6. Arvio P., Arvio M., Wolf J., Lukinmaa P. L., Saxen L., Pirinen S. Impaired oral health in patients with aspartylglucosaminuria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):562–568. doi: 10.1016/s1079-2104(98)90346-8. [DOI] [PubMed] [Google Scholar]
  7. Berg M., Lidén S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69(5):419–423. [PubMed] [Google Scholar]
  8. Bonnaure-Mallet M., Tricot-Doleux S., Godeau G. J. Changes in extracellular matrix macromolecules in human gingiva after treatment with drugs inducing gingival overgrowth. Arch Oral Biol. 1995 May;40(5):393–400. doi: 10.1016/0003-9969(94)00187-g. [DOI] [PubMed] [Google Scholar]
  9. Enomaa N. E., Lukinmaa P. L., Ikonen E. M., Waltimo J. C., Palotie A., Paetau A. E., Peltonen L. Expression of aspartylglucosaminidase in human tissues from normal individuals and aspartylglucosaminuria patients. J Histochem Cytochem. 1993 Jul;41(7):981–989. doi: 10.1177/41.7.7685790. [DOI] [PubMed] [Google Scholar]
  10. Enomaa N., Heiskanen T., Halila R., Sormunen R., Seppälä R., Vihinen M., Peltonen L. Human aspartylglucosaminidase. A biochemical and immunocytochemical characterization of the enzyme in normal and aspartylglucosaminuria fibroblasts. Biochem J. 1992 Sep 1;286(Pt 2):613–618. doi: 10.1042/bj2860613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Flanagan N., O'Connor W. J., McCartan B., Miller S., McMenamin J., Watson R. Developmental enamel defects in tuberous sclerosis: a clinical genetic marker? J Med Genet. 1997 Aug;34(8):637–639. doi: 10.1136/jmg.34.8.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Halila R., Baumann M., Ikonen E., Enomaa N., Peltonen L. Human leucocyte aspartylglucosaminidase. Evidence for two different subunits in a more complex native structure. Biochem J. 1991 May 15;276(Pt 1):251–256. doi: 10.1042/bj2760251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ikonen E., Aula P., Grön K., Tollersrud O., Halila R., Manninen T., Syvänen A. C., Peltonen L. Spectrum of mutations in aspartylglucosaminuria. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11222–11226. doi: 10.1073/pnas.88.24.11222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ikonen E., Baumann M., Grön K., Syvänen A. C., Enomaa N., Halila R., Aula P., Peltonen L. Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease. EMBO J. 1991 Jan;10(1):51–58. doi: 10.1002/j.1460-2075.1991.tb07920.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jalanko A., Manninen T., Peltonen L. Deletion of the C-terminal end of aspartylglucosaminidase resulting in a lysosomal accumulation disease: evidence for a unique genomic rearrangement. Hum Mol Genet. 1995 Mar;4(3):435–441. doi: 10.1093/hmg/4.3.435. [DOI] [PubMed] [Google Scholar]
  16. Laitinen A., Hietala M., Haworth J. C., Schroeder M. L., Seargeant L. E., Greenberg C. R., Aula P. Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation. Clin Genet. 1997 Mar;51(3):174–178. doi: 10.1111/j.1399-0004.1997.tb02448.x. [DOI] [PubMed] [Google Scholar]
  17. Lygidakis N. A., Lindenbaum R. H. Oral fibromatosis in tuberous sclerosis. Oral Surg Oral Med Oral Pathol. 1989 Dec;68(6):725–728. doi: 10.1016/0030-4220(89)90162-x. [DOI] [PubMed] [Google Scholar]
  18. Mononen I., Heisterkamp N., Kaartinen V., Mononen T., Williams J. C., Groffen J. Aspartylglycosaminuria in a non-Finnish patient caused by a donor splice mutation in the glycoasparaginase gene. J Biol Chem. 1992 Feb 15;267(5):3196–3199. [PubMed] [Google Scholar]
  19. Mononen I., Heisterkamp N., Kaartinen V., Williams J. C., Yates J. R., 3rd, Griffin P. R., Hood L. E., Groffen J. Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycoasparaginase. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2941–2945. doi: 10.1073/pnas.88.7.2941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mättä A., Järveläinen H. T., Nelimarkka L. O., Penttinen R. P. Fibroblast expression of collagens and proteoglycans is altered in aspartylglucosaminuria, a lysosomal storage disease. Biochim Biophys Acta. 1994 Feb 22;1225(3):264–270. doi: 10.1016/0925-4439(94)90005-1. [DOI] [PubMed] [Google Scholar]
  21. Näntö-Salonen K., Pelliniemi L. J., Autio S., Kivimäki T., Rapola J., Penttinen R. Abnormal collagen fibrils in aspartylglycosaminuria. Altered dermal ultrastructure in a glycoprotein storage disorder. Lab Invest. 1984 Oct;51(4):464–468. [PubMed] [Google Scholar]
  22. Näntö-Salonen K., Penttinen R. Metabolism of collagen in aspartylglycosaminuria: decreased synthesis by cultured fibroblasts. J Inherit Metab Dis. 1982;5(4):197–203. doi: 10.1007/BF02179141. [DOI] [PubMed] [Google Scholar]
  23. Park H., Rossiter M., Fensom A. H., Winchester B., Aronson N. N., Jr Single base deletion in exon 7 of the glycosylasparaginase gene causes a mild form of aspartylglycosaminuria in a patient of Mauritian origin. J Inherit Metab Dis. 1996;19(1):76–83. doi: 10.1007/BF01799351. [DOI] [PubMed] [Google Scholar]
  24. Park H., Vettese M. B., Fensom A. H., Fisher K. J., Aronson N. N., Jr Characterization of three alleles causing aspartylglycosaminuria: two from a British family and one from an American patient. Biochem J. 1993 Mar 15;290(Pt 3):735–741. doi: 10.1042/bj2900735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Peltola M., Chiatayat D., Peltonen L., Jalanko A. Characterization of a point mutation in aspartylglucosaminidase gene: evidence for a readthrough of a translational stop codon. Hum Mol Genet. 1994 Dec;3(12):2237–2242. doi: 10.1093/hmg/3.12.2237. [DOI] [PubMed] [Google Scholar]
  26. Peltola M., Tikkanen R., Peltonen L., Jalanko A. Ser72Pro active-site disease mutation in human lysosomal aspartylglucosaminidase: abnormal intracellular processing and evidence for extracellular activation. Hum Mol Genet. 1996 Jun;5(6):737–743. doi: 10.1093/hmg/5.6.737. [DOI] [PubMed] [Google Scholar]
  27. Roed-Petersen B., Renstrup G. A topographical classification of the oral mucosa suitable for electronic data processing. Its application to 560 leukoplakias. Acta Odontol Scand. 1969 Dec;27(6):681–695. doi: 10.3109/00016356909026317. [DOI] [PubMed] [Google Scholar]
  28. Tikkanen R., Riikonen A., Oinonen C., Rouvinen R., Peltonen L. Functional analyses of active site residues of human lysosomal aspartylglucosaminidase: implications for catalytic mechanism and autocatalytic activation. EMBO J. 1996 Jun 17;15(12):2954–2960. [PMC free article] [PubMed] [Google Scholar]
  29. Webb D. W., Clarke A., Fryer A., Osborne J. P. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol. 1996 Jul;135(1):1–5. [PubMed] [Google Scholar]
  30. Yoshida K., Yanagisawa N., Oshima A., Sakuraba H., Iida Y., Suzuki Y. Splicing defect of the glycoasparaginase gene in two Japanese siblings with apartylglucosaminuria. Hum Genet. 1992 Sep-Oct;90(1-2):179–180. doi: 10.1007/BF00210771. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES